NCT04343729View on ClinicalTrials.gov

Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19

PHASE2CompletedINTERVENTIONAL

Enrollment

416

Participants

Timeline

Start Date

April 18, 2020

Primary Completion Date

June 16, 2020

Study Completion Date

October 20, 2020

Conditions

SARS-CoV InfectionSevere Acute Respiratory Syndrome (SARS) Pneumonia

Interventions

DRUG

Methylprednisolone Sodium Succinate

injectable solution at a dose of 0.5mg/kg

DRUG

Placebo solution

injectable saline solution

Trial Locations (1)

69093-415

Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus

All Listed Sponsors

lead

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

OTHER

NCT04343729 - Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19 | Biotech Hunter | Biotech Hunter